LAG3 Expression in Triple Negative Breast Cancer

Samsung Medical Center

Status: Enrolling

Conditions: Immune Checkpoint Inhibitor; Triple Negative Breast Cancer

Treatments: Procedure: LAG-3 expression / immune checkpoint protein expression

Study type: Interventional

Funder types: Other

Identifiers

NCT06259162

LAG3_Breast

Details and patient eligibility

About

This study is the experimental study for relationship between LAG-3 expression / immue checkpoint protein expression and neoadjuvant chemotherapy plus immune checkpoint inhibitor in triple negative breast cancer.

Enrollment: 128 estimated patients

Sex: Female

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Planned neoadjuvant chemotherapy
• Triple negative breast cancer

Exclusion criteria

• HER2-positive breast cancer
• Hormone receptor positive breast cancer

Trial design

Primary purpose: Screening

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

128 participants in 1 patient group

LAG-3 expression/immune checkpoint protein expression evaluation

Experimental group

Treatment:

Procedure: LAG-3 expression / immune checkpoint protein expression